TMCnet News
Sarcopenia Epidemiology Forecast to 2023: Focus on US, France, Germany, Italy, Spain, UK and Japan - Research and MarketsResearch and Markets has announced the addition of the "Sarcopenia - Epidemiology Forecast to 2023" report to their offering. The prevalent cases of Sarcopenia in 7MM are expected to increase and reach up to 42,969,489 cases by the end of year 2023. Sarcopenia - Epidemiology Forecast to 2023 report provides an overview of the epidemiology trends of Sarcopenia in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes historical and forecasted epidemiological data for the prevalent cases of Sarcopenia from 2013-2023. Sarcopenia is the progressive loss of skeletal muscle that comes with aging. Sarcopenia is multifactorial in cause. Most people begin to lose modest amounts of muscle mass ater age 30, but the resulting loss of strength increases exponentially with age. Of the contributory factors relating to the development of sarcopenia inadequate protein intake, increased splanchnic extraction of amino acids, decreased muscular response to postprandial anabolic stimuli and vitamin D deficiency are directly related to nutrition. Key Topics Covered: 1. Report Introduction Sarcopenia: Overview Pathophysiology Symptoms Diagnosis Sarcopenia categories and stages 2. EWGSOP Conceptual Stages of Sarcopenia Treatment Challenges Unmet Need 3. Epidemiology of Sarcopenia in 7MM 4. Epidemiology and Patient Population 5. Assumptions and Caveats 6. Prevalent Population of Sarcopenia in 7MM United States Europe United Kingdom France Italy Spain Germany Japan For more information about this report visit http://www.researchandmarkets.com/research/tprqln/sarcopenia
View source version on businesswire.com: http://www.businesswire.com/news/home/20170407005212/en/ |
